FAQ | Fact Sheet | Media Page

Corporate Information

2635 Technology Forest Blvd.

The Woodlands, TX 77381

Phone: (281) 775-0600
Fax: (281) 872-8585

www.opexatherapeutics.com

Recent News Releases

OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and

Friday, May 11, 2012

Opexa Therapeutics Reports First Quarter 2012 Financial Results and Provides Corporate Update

Friday, May 11, 2012

[Business Wire] - Opexa Therapeutics, Inc. , a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis , today reported financial results for the quarter ended Ma

Opexa to Hold Preliminary Investigator’s Meeting for MS Trial at American Academy of Neurology Annual Meeting

Thursday, Apr 19, 2012

[Business Wire] - Opexa Therapeutics, Inc. , a biotechnology company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis , announced today that the Company will be holding a preliminary meeting with prospective clinical trial investigators at the 64th Annual American Academy of Neurology Meeting in New Orleans on April 24, 2012.

Follow Crystal Research

Opexa Therapeutics, Inc. (formerly PharmaFrontiers Corp.)

Corporate Snapshot

Opexa Therapeutics, Inc. (formerly PharmaFrontiers Corp.) is a biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis (MS), cardiovascular disease, and diabetes. These therapies are based on the Company's proprietary T-cell and stem cell technologies. Opexa Therapeutics' lead product, Tovaxin™, is a T-cell-based therapeutic vaccine for MS, offering a unique and personalized approach to treating the disease by inducing an immune response against the autoimmune myelin-reactive T-cells (MRTCs). Tovaxin™ is currently in Phase I/II clinical trials and is cleared by the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) to enter a Phase IIb trial in the first quarter of 2006. Initial human trials show that T-cell vaccination (TCV) safely induces immune responses that deplete and regulate myelin-peptide reactive T-cells, thus stabilizing the disease, with the majority of patients showing improvement. Moreover, the Company is evaluating T-cell assay technology, which can be used to monitor T-cell therapy and possibly develop a product for early diagnosis of MS. Opexa Therapeutics also holds the exclusive worldwide license to adult pluripotent stem cells derived from peripheral blood monocytes that allow for the isolation, propagation, and differentiation into cells and tissues for patient-specific cell-based therapies. Opexa Therapeutics is currently pursuing indications for congestive heart failure (CHF) and Type 1 diabetes with its stem cell technology. The Company also expects to conduct basic research to determine the potential use of its stem cells in other indications, such as macular degeneration, stroke, and Parkinson's disease. Opexa Therapeutics is headquartered in The Woodlands, Texas.